通过调节PI3K-Akt通路,通过Corydalis decumbens抑制的血栓形成
Song Chen1, Cai-Bo Tian1, Li-Yu Bai1
1Yunnan Characteristic Plant Extraction Laboratory, Key Laboratory of Medicinal Chemistry for Natural Resource, Ministry of Education, Yunnan Key Laboratory of Research and Development for Natural Products, School of Pharmacy, School of Chemical Science and Technology, Yunnan University, Kunming, 650091, PR China.
Journal of ethnopharmacology
|April 11, 2024
概括
科里达利斯虫通过抑制PI3K-Akt通路表现出抗血栓作用. 这项研究支持其传统用途,并确定了潜在的治疗性化物用于心血管疾病.
科学领域:
- 药理学 药理学是指药理学的学科.
- 传统中国医药 传统中国医药
- 心血管研究研究心血管研究
背景情况:
- 科里达利斯 (Corydalis decumbens,Thunb.) 是一种的植物. 个人 个人 个人 传统上用于心血管疾病,具有抗血栓作用.
- 药理学证据支持其抗血栓性质是有限的.
研究的目的:
- 为了研究Corydalis decumbens的抗血栓作用.
- 阐明其行动背后的初步机制.
主要方法:
- 在体内血栓形成模型 (卡拉基南诱导的小鼠血栓,ADP刺激的子血小板聚合).
- 在体外内皮细胞损伤模型 (H2O2诱导的HUVECs).
- 在基网络药理学和分子对接中,通过西式涂抹验证.
主要成果:
- C. decumbens 提取物和类化合物 (四基胺,原胺) 显著减少了血栓形成和血小板聚合.
- 生物活性化合物保护HUVECs免受氧化损伤,减少ROS和LDH的释放.
- 网络药理学确定PI3K-Akt是关键途径,其中HSP90AA1,COX-2,NF-κB/p65,MMP1和HIF-1α是主要目标,西部涂抹证实了这一点.
结论:
- 科里达利斯虫通过抑制PI3K-Akt信号通路显示出抗血栓活性.
- 这些发现支持C. decumbens的传统使用,并强调其作为抗血栓剂来源的潜力.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
689
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
689
PI3K/mTOR/AKT Signaling Pathway
3.5K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.5K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
522
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
522
Clot Retraction and Fibrinolysis
5.7K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
5.7K
IP3/DAG Signaling Pathway
12.0K
Membrane lipids such as phosphatidylinositol (PI) are precursors for several membrane-bound and soluble second messengers. Specific kinases phosphorylate PI and produce phosphorylated inositol phospholipids. One such inositol phospholipids are the phosphatidylinositol-4,5 bisphosphate [PI(4,5)P2], present in the inner half of the lipid bilayer. Upon ligand binding, GPCR stimulates Gq proteins to turn on phospholipase Cꞵ. Activated phospholipase Cꞵ cleaves PI(4,5)P2 and...
12.0K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
170
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
170


